Updated guidance from the National Institute for Health and Care Excellence (NICE) on the diagnosis and management of chronic heart failure in adults consolidates several clinically significant recommendations, with particular attention to pharmacological optimization across ejection fraction subtypes and the expanding role of intravenous iron supplementation. The guidance arrives at a consequential moment: data from the 2025 National Heart Failure Audit document a rise in index hospital admissions for heart failure from 61,401 in 2022/23 to 65,679 in 2023/24, a trajectory that underscores both the growing prevalence of the condition and the pressure it places on healthcare infrastructure.

Across Europe, heart failure affects an estimated 1 to 2 percent of adults, a figure that translates into millions of individuals managing a condition associated with substantial morbidity, repeated hospitalization, and reduced quality of life. In the United Kingdom, the cumulative burden on outpatient services, inpatient wards, and community care teams is considerable. Against this background, the updated NICE guidance aims to standardize care, reduce variation in treatment, and ensure that clinicians apply the current evidence base systematically across the full spectrum of heart failure phenotypes.

Pharmacological Management of Heart Failure With Reduced Ejection Fraction

The pharmacological core of the updated guidance centers on a four-drug foundational regimen for patients with heart failure with reduced ejection fraction (HFrEF), defined by a left ventricular ejection fraction (LVEF) at or below 40 percent. Clinicians are directed to offer all four of the following drug classes: angiotensin converting enzyme (ACE) inhibitors, beta blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose co-transporter-2 (SGLT2) inhibitors.

This quadruple therapy framework reflects the maturation of the evidence base that accumulated over the preceding decade. ACE inhibitors and beta blockers established the foundation of neurohormonal blockade in HFrEF over prior decades, with robust mortality benefit documented across multiple large randomized controlled trials (RCTs). MRAs, including spironolactone and eplerenone, subsequently demonstrated additive benefit through aldosterone antagonism in patients with reduced ejection fraction. The incorporation of SGLT2 inhibitors, originally developed as glucose-lowering agents in type 2 diabetes mellitus, represents the most recent and consequential expansion of this therapeutic framework. Trials including DAPA-HF and EMPEROR-Reduced established that dapagliflozin and empagliflozin, respectively, reduced the composite of worsening heart failure and cardiovascular death in patients with HFrEF, regardless of diabetic status. NICE now formalizes this evidence by positioning SGLT2 inhibitors as a standard rather than adjunctive component of treatment.

For patients with heart failure with mildly reduced ejection fraction (HFmrEF), characterized by an LVEF between 41 and 49 percent, the guidance recommends that clinicians consider all four drug classes. The evidence base in this subgroup is less mature than in HFrEF, reflecting the historical underrepresentation of HFmrEF patients in landmark trials. Nevertheless, the physiological rationale for neurohormonal blockade remains relevant, and subgroup analyses from major trials have suggested benefit in this ejection fraction range. The guidance appropriately uses “consider” rather than “offer” to reflect the current evidentiary gradient.

Intravenous Iron in Heart Failure With Reduced Ejection Fraction

One of the more clinically actionable additions to the updated guidance addresses the management of iron deficiency in patients with HFrEF. NICE now recommends that clinicians consider intravenous iron for patients with HFrEF who have a haemoglobin concentration below 150 grams per litre and who meet criteria for iron deficiency.

Iron deficiency is prevalent in heart failure, affecting approximately 30 to 50 percent of patients across various cohorts, and frequently coexists with or occurs independently of anaemia. The mechanisms by which iron deficiency impairs cardiac and skeletal muscle function involve disruption of mitochondrial respiration and oxidative phosphorylation, pathways that are particularly sensitive to intracellular iron availability. Clinically, iron deficiency in heart failure associates with reduced exercise tolerance, worsened functional class, and poorer outcomes.

The AFFIRM-AHF and IRONMAN trials provided key evidence supporting intravenous ferric iron supplementation in this context. Intravenous administration is preferred over oral supplementation in heart failure because gut absorption of oral iron is frequently impaired due to upregulation of hepcidin, an iron-regulatory peptide that restricts duodenal iron transport in the setting of chronic inflammation. Ferric carboxymaltose and ferric derisomaltose represent the agents most studied in this population, with evidence suggesting improvements in exercise capacity, quality of life, and reductions in heart failure hospitalization, though the mortality signal has remained less definitive across individual trials. The haemoglobin threshold of 150 grams per litre specified in the NICE guidance provides a practical ceiling, acknowledging that iron supplementation in this context targets the iron-deficient rather than the severely anaemic patient, and that other causes of anaemia require concurrent evaluation.

Heart Failure With Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF), defined by an LVEF at or above 50 percent, has long represented the more therapeutically intractable of the major heart failure phenotypes. Unlike HFrEF, where neurohormonal blockade produces consistent mortality reduction, HFpEF has resisted multiple pharmacological strategies across decades of clinical investigation. The updated NICE guidance reflects a measured shift in this position, recommending that clinicians consider SGLT2 inhibitors and MRAs for patients with HFpEF.

The EMPEROR-Preserved trial, which evaluated empagliflozin in patients with HFpEF, reported a statistically significant reduction in the composite of cardiovascular death and hospitalization for heart failure, driven predominantly by the hospitalization component. The DELIVER trial subsequently replicated directionally similar findings with dapagliflozin. These results represent the first pharmacological agents to demonstrate meaningful endpoint reduction in HFpEF in large RCTs, and their incorporation into NICE guidance reflects the strength of that cumulative evidence. The mechanism of benefit in HFpEF likely involves multiple pathways, including reductions in cardiac preload and afterload through natriuresis and osmotic diuresis, attenuation of cardiac fibrosis and inflammation, and potentially direct cardiomyocyte effects.

The recommendation to consider MRAs in HFpEF rests on a more modest evidence base. The TOPCAT trial of spironolactone in HFpEF produced mixed results overall, though post-hoc regional analyses raised methodological questions that complicated interpretation. Subsequent smaller trials and meta-analyses have suggested a potential benefit in symptoms and hospitalization, and the guidance acknowledges this by employing the qualifier “consider” rather than mandating routine use.

Diagnostic Considerations

The updated guidance reinforces the diagnostic pathway for chronic heart failure, emphasizing that a diagnosis should integrate clinical assessment, measurement of natriuretic peptides including N-terminal pro-B-type natriuretic peptide (NT-proBNP) or B-type natriuretic peptide (BNP), and echocardiographic evaluation. Natriuretic peptide thresholds serve as gatekeeping criteria for echocardiography referral, with elevated values in symptomatic patients triggering specialist assessment to confirm diagnosis and characterize ejection fraction subtype.

Accurate ejection fraction classification is not merely a diagnostic formality. It carries direct therapeutic consequences under the updated guidance, determining which drug classes are offered, which are considered, and which remain outside current recommendations. Clinicians must therefore ensure that echocardiographic measurements are current and performed under optimal technical conditions, as ejection fraction classification errors may result in either under-treatment or inappropriate therapy.

Monitoring and Follow-Up

The guidance emphasizes structured follow-up for patients with established heart failure, including regular reassessment of symptoms, fluid status, renal function, and electrolytes, particularly following initiation or uptitration of ACE inhibitors, MRAs, and SGLT2 inhibitors. Renal function and potassium require monitoring when combining agents with potassium-retaining properties, given the additive risk of hyperkalaemia with ACE inhibitors and MRAs. SGLT2 inhibitors generally carry a favorable renal profile in heart failure populations, though volume status and the potential for urogenital infections warrant clinical attention.

Device therapy, including cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs), remains within scope for eligible patients with HFrEF, and the guidance reaffirms the importance of specialist cardiology input in determining candidacy for device-based interventions.